The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1419
ISSUE 1419
June 24, 2013
Issue 1419
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Liptruzet: A Combination of Ezetimibe and Atorvastatin
June 24, 2013 (Issue: 1419)
The FDA has approved a fixed-dose combination of
the cholesterol absorption inhibitor ezetimibe and the
HMG-CoA reductase inhibitor (statin) atorvastatin as
Liptruzet (Merck) for treatment of hyperlipidemia.
Ezetimibe is also available in a...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.